Yao Chih-Jung, Chow Jyh-Ming, Lin Pei-Chun, Hu Tsai-Shu, Kuo Hui-Ching, Huang Jhy-Shrian, Bai Kuan-Jen, Lai Gi-Ming
Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan; Comprehensive Cancer Center of Taipei Medical University, Taipei 11031, Taiwan; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Evid Based Complement Alternat Med. 2016;2016:5989681. doi: 10.1155/2016/5989681. Epub 2016 Dec 18.
Lung cancer is the leading cause of cancer death worldwide; the most common pathologic type is lung adenocarcinoma (LADC). In spite of the recent progress in targeted therapy, most LADC patients eventually expired due to the inevitable recurrence and drug resistance. New complementary agent with evidence-based molecular mechanism is urgently needed. MiR-34a is an important p53 downstream tumor suppressor, which regulates apoptosis, cell-cycle, EMT (epithelial mesenchymal transition), and so forth. Its expression is deficient in many types of cancers including LADC. Here, we show that a Chinese herbal formula JP-1 activates p53/miR-34a axis in A549 human LADC cells (p53 wild-type). Treatment with JP-1 induces p53 and its downstream p21 and BAX proteins as well as the miR-34a, resulting in growth inhibition, colony formation reduction, migration repression, and apoptosis induction. Accordingly, the decreases of miR-34a downstream targets such as CDK6, SIRT1, c-Myc, survivin, Snail, and AXL were observed. Moreover, JP-1 activates AMPK and reduces mTOR activity, implying its inhibitory effect on the energy-sensitive protein synthesis and cell proliferation signaling. Our results show that JP-1 activates p53/miR-34a tumor suppressor axis and decreases proteins related to proliferation, apoptosis resistance, and metastasis, suggesting its potential as a complementary medicine for LADC treatment.
肺癌是全球癌症死亡的主要原因;最常见的病理类型是肺腺癌(LADC)。尽管靶向治疗最近取得了进展,但大多数LADC患者最终还是因不可避免的复发和耐药而死亡。迫切需要具有循证分子机制的新型辅助药物。MiR-34a是一种重要的p53下游肿瘤抑制因子,可调节细胞凋亡、细胞周期、上皮间质转化(EMT)等。其表达在包括LADC在内的多种癌症中均有缺失。在此,我们表明一种中药配方JP-1可激活A549人LADC细胞(p53野生型)中的p53/miR-34a轴。用JP-1处理可诱导p53及其下游的p21和BAX蛋白以及miR-34a,从而导致生长抑制、集落形成减少、迁移抑制和凋亡诱导。相应地,观察到miR-34a下游靶点如CDK6、SIRT1、c-Myc、survivin、Snail和AXL的减少。此外,JP-1激活AMPK并降低mTOR活性,这意味着其对能量敏感的蛋白质合成和细胞增殖信号传导具有抑制作用。我们的结果表明,JP-1激活p53/miR-34a肿瘤抑制轴,并减少与增殖、抗凋亡和转移相关的蛋白质,表明其作为LADC治疗辅助药物的潜力。